SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Screening Program to enable it to furnish complete and accurate information to Tularik regarding the Screening Program activities and results, including all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified in the Screening Program and all Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. All such written records of NeoGenesis shall be open to inspection by Tularik during normal business hours upon reasonable prior notice. (b) NeoGenesis shall provide Tularik with reasonably-detailed written reports describing the results of the research performed pursuant to the Screening Program including all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified in the Screening Program and Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. Such reports shall be delivered to Tularik at least monthly during the Screening Program. Representatives of NeoGenesis will make themselves reasonably available to discuss such reports and the progress of the Screening Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Screening Program work performed on each Target including a description of all the Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified during the Screening Program with respect to such Target.
Appears in 2 contracts
Sources: Confidentiality Agreement (Neogenesis Pharmaceuticals Inc), Service Agreement (Neogenesis Pharmaceuticals Inc)